血清HK10、IL-37水平与贝伐珠单抗联合TP方案化疗晚期卵巢癌效果的相关性分析  

Analyzsis of the correlation between serum HK10,IL-37 levels and the effect of bevacizumab combined with TP regimen chemotherapy in advanced ovarian cancer

作　　者：车慧敏 姚田 陶嫄 CHE Huimin;YAO Tian;TAO Yuan(Gynecology and Obstetrics Department,Xi'an People's Hospital/Xi'an Fourth Hospital,Xi'an 710004,China)

机构地区：[1]西安市人民医院/西安市第四医院妇产科,陕西西安710004

出　　处：《临床医学研究与实践》2023年第28期26-29,共4页Clinical Research and Practice

基　　金：西安市卫生健康委员会科研项目(No.2021qn02)。

摘　　要：目的分析血清激肽释放酶10(HK10)、白细胞介素-37(IL-37)与贝伐珠单抗联合TP方案化疗晚期卵巢癌效果的相关性。方法选择2018年1月至2021年12月在本院接受诊治的97例晚期卵巢癌患者为研究对象,患者均接受4个周期的贝伐珠单抗联合TP方案化疗。依据化疗效果将其分为缓解组和未缓解组。比较两组的临床资料及血清指标,分析影响患者化疗效果的危险因素及HK10、IL-37水平预测卵巢癌化疗效果的效能。结果持续治疗4个周期后,缓解63例,未缓解34例。未缓解组的国际妇产科联盟(FIGO)Ⅳ期、肿瘤最大径≥1 cm、肿瘤低分化、肌层浸润程度≥1/2、淋巴转移占比及血清HK10、IL-37水平均显著高于缓解组,差异具有统计学意义(P<0.05)。Logistic回归分析显示,低分化、淋巴转移及血清HK10、IL-37高水平均是影响患者化疗效果的危险因素(P<0.05)。血清HK10、IL-37均对晚期卵巢癌化疗效果具有较好预测效能。结论晚期卵巢癌患者血清HK10、IL-37水平与贝伐珠单抗联合TP方案的化疗效果有关,可作为预测化疗效果的潜在指标。Objective To analyze the correlation between serum human kallikrein 10(HK10)and interleukin-37(IL-37)and the effect of bevacizumab combined with TP regimen chemotherapy in advanced ovarian cancer.Methods A total of 97 patients with advanced ovarian cancer diagnosed and treated in our hospital from January 2018 to December 2021 were selected as the study subjects.All patients received 4 cycles of bevacizumab combined with TP regimen chemotherapy.According to the chemotherapy effect,the patients were divided into remission group and non-remission group.The clinical data and serum indexes of the two groups were compared,and the risk factors affecting the chemotherapy effect of patients and the efficacy of HK10 and IL-37 levels in predicting the chemotherapy effect of ovarian cancer were analyzed.Results After 4 cycles of continuous treatment,63 cases were relieved and 34 cases were not relieved.The International Federation of Obstetrics and Gynaecology(FIGO)stageⅣ,tumor maximum diameter≥1 cm,tumor low differentiation,myometrial invasion degree≥1/2,lymph node metastasis ratio,serum HK10 and IL-37 levels in the non-remission group were significantly higher than those in the remission group,and the differences were statistically significant(P<0.05).Logistic regression analysis showed that low differentiation,lymph node metastasis and high levels of serum HK10 and IL-37 were risk factors affecting the chemotherapy effect(P<0.05).Serum HK10 and IL-37 have good predictive efficacy for the chemotherapy effect of advanced ovarian cancer.Conclusion The levels of serum HK10 and IL-37 in patients with advanced ovarian cancer are related to the chemotherapy effect of bevacizumab combined with TP regimen,which can be used as potential indexes to predict the chemotherapy effect.

关 键 词：激肽释放酶10 白细胞介素-37 贝伐珠单抗 TP方案 晚期卵巢癌 预测效能 

分 类 号：R956[医药卫生—药学]